Summary:
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures. (if not interested in phase 1b there may be other opportunities for this indication at the site.)
Qualified Participants Must:
• Be having focal seizures on a regular basis and have not been able to control seizures adequately with current medications.
Qualified Participants May Receive:
A Cannabidiol oral solution that is currently on the market for other indications under the name Epidiolex. Patients may also be compensated up to $100.00 per completed clinic visit and up to $50.00 per phone call visit. This study is open label so there is no chance of placebo.